Does bupropion have advantages over other medical therapies in the cessation of smoking?

Bibliography

• FIORE MC, BAILEY W, COHEN SJ iet al.: i Treating tobacco use and dependence. U. S. Department of Health and Human Services: iAgency for Healthcare Research Quality i Rockville, MD, USA (2000).
   Google Scholar
• BALFOUR DJK: The psychopharmacology of tobacco dependence. I. iClin. Psychiatry i iMonograph. i (2003) b18:12-21. b
   Google Scholar
• Nicotine replacement therapy (NRT) and bupropion for smoking cessation. iNational Institute for Clinical Excellence, i London Technology Appraisal Guidance No. 38 (2002).
   Google Scholar
• •Authoritative guidance on the efficacy and safety of NRT and bupropion.
   Google Scholar
• HUGHES JR, STEAD LF, LANCASTER T: Antidepressants for smoking cessation (Cochrane Review). In: iThe Cochrane Library i Issue 4 (2003). John Wiley & Sons, Ltd, Chichester, UK.
   Google Scholar
• •A definitive meta-analysis of bupropion and antidepressants.
   Google Scholar
• HOLM KJ, SPENCER CM: Bupropion. A review of its use in smoking cessation. iDrugs i (2000) 59:1007–1024.
   Google Scholar
• JORENBY D: Clinical efficacy of bupropion in the management of smoking cessation. iDrugs i (2002) 62\(Suppl. 2):25–35.
   Google Scholar
• WEST R: Bupropion SR for smoking cessation. iExpert Opin. Pharmacother: i (2003) 4:533–540.
   PubMed Web of Science ®Google Scholar
• RICHMOND R, ZWAR N: Review of bupropion for smoking cessation. iDrug Alcohol Rev i (2003) 22:203–220.
   PubMed Web of Science ®Google Scholar
• HURT RD, SACHS DPL, GLOVER ED iet al.: i A comparison of sustained release bupropion and placebo for smoking cessation. iN Engl. J. Med. i (1997) 337:1195–1202.
   Google Scholar
• •A pivotal dose-response study.
   Google Scholar
• JORENBY DE, LEISCHOW SJ, NIDES MA iet al.: i A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. iN Engl. J. Med. i (1999) 340:685–691.
   Google Scholar
• •A pivotal comparative trial.
   Google Scholar
• TONNESSEN P, TONSTAD S, HJALMARSON A iet al: i A multicenter, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. iJ. Intern. Med. i (2003) 254:184–192.
   PubMedGoogle Scholar
• TASHKIN DP, KANNER R, BAILEY W iet al.: i Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. iLancet i (2001) 357:1571–1575.
   Google Scholar
• TONSTAD S, FARSANG C, KLAENE G iet al.: i Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. iEur. Heart" i (2003) 24:946–955.
   Google Scholar
• AHLUWALIA JS, HARRIS KJ, CATLEY D, OKUYEMI KS, MAYO MS: Sustained-release bupropion for smoking cessation in African Americans. i"AMA i (2002) 288:468–474.
   Google Scholar
• HALL SM, HUMFLEET GL, REUS VI, MUNOZ RF, HARTZ DT, MAUDE-GRIFFIN R: Psychological intervention and antidepressant treatment in smoking cessation. iArch. Gen. Psychiatry i (2002) 59:930–936.
   PubMed Web of Science ®Google Scholar
• NIELSEN K, FIORE MC: Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation. iPrey Med. i (2000) 30:209–216.
   Google Scholar
• WOOLACOTT NF, JONES L, FORBES CA iet al: i The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. iHealth Technol Assess. i (2002) 6:No. 16.
   Google Scholar
• •A very comprehensive overview.
   Google Scholar
• FAGERSTROM KO: Clinical treatment of tobacco dependence: the endurance of pharmacologic efficacy. I. iClin. Psychiatry Monograph. i (2003) 18(1):35–40.
   Google Scholar
• HAYS JT, HURT RD, RIGOTTI NA iet al.: i Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. iAnn. Intern. Med. i (2001) 135:423–433.
   Google Scholar
• SHIFFMAN S, JOHNSTON JA, KHAYRALLAH M iet al.: i The effect of bupropion on nicotine craving and withdrawal. iPsychopharmacology i (2000) 148:33–40.
   Google Scholar
• DURCAN MJ, DEENER G, WHITE JD iet al.: i The effect of bupropion sustained-release on cigarette craving after smoking cessation. iClin. Ther. i (2002) 24:540–551.
   Google Scholar
• HUGHES JR, SHIFFMAN S, CALLAS P, ZHANG J: A meta-analysis of the efficacy of over-the counter nicotine replacement. iTob. Control i (2003) 1:21–27.
   Google Scholar
• GOLD PB, RUBEY RN, HARVEY RT: Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care. iAm. J. Addict. i (2002) 11:315–331.
   Google Scholar
• HOLMES SC, BROWNING DC, POWELL S, MARSH H: Real-world smoking cessation rates with bupropion SR in general practice in the UK. In: iJ' European Conference on Tobacco or Health, i Warsaw, Poland (2002).
   Google Scholar
• ZWAR NA, NASSER A, COMINO E, RICHMOND RL: Short-term effectiveness of bupropion for assisting smoking cessation in general practice. iMed.". Aust. i (2002) 177:277–278.
   PubMedGoogle Scholar
• SWAN GE, MCAFEE T, CURRY SJ iet al: iEffectiveness of bupropion sustained release for smoking cessation in a health care setting. iArch. Intern. Med. i (2003) 163:2337–2344.
   PubMed Web of Science ®Google Scholar
• JACK LM, SWAN GE, THOMPSON E iet al.: i Burpopion SR and smoking cessation in actual practice: methods for recruitment, screening, and exclusion for a field trial in a managed care setting. iPrey Med. i (2003) 36:585–593.
   Google Scholar
• HURT RD, KROOK JE, CROGHAN IT iet al.: i Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J. iClin. Oncol i (2003) 21:914–920.
   Google Scholar
• GOURLAY SG, FORBES A, MARRINERT, PETHICA D, MCNEIL JJ: Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. iBr. Med. J. i (1995) 311:363–366.
   PubMed Web of Science ®Google Scholar
• GONZALES DH, NIDES MA, FERRY LH iet al.: i Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. iClin. Pharmacol Ther: i (2001) 69:438–444.
   Google Scholar
• SELBY P, BROSKY G, BAKER R, LERTZMAN M, DAKIN P, ROBERTS J: Bupropion SR is effective in the re-treatment of relapsed adult smokers. In: ..7d iEuropean Conference of the Socieh, i ifor Research on Nicotine and Tobacco, i Paris, France (2001).
   Google Scholar
• JAMERSON BD, NIDES M, JORENBY DE iet al.: i Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. iClin. Ther. i (2001) 23:744–752.
   Google Scholar
• BERGMANN L, WARNCK W, MERSCHEL M, JOHNSTON JA: Real-life efficacy of bupropion sustained-release in relapsed smokers. In: 5th iEuropean i Conference of the Society for Research on iNicotine and Tobacco, i Padova, Italy (2003).
   Google Scholar
• DURCAN MJ, WHITE J, JORENBY DE iet al.: i Impact of prior nicotine replacement therapy on smoking cessation efficacy. iAm. J. Health Behav. i (2002) 26:213–220.
   Google Scholar
• DALE LC, GLOVER ED, SACHS DPL iet al.: i Bupropion for smoking cessation. Predictors of successful outcome. iChest (2001) i 119:1357–1364.
   Google Scholar
• SMITH SS, JORENBY DE, LEIS CHOW SJ iet al.: i Targeting smokers at increased risk for relapse: treating women and those with a history of depression. iNicotine Tob. Res. i (2003) 5:99–109.
   Google Scholar
• SCHARF D, SHIFFMAN S: Are women less able to quit smoking than men? A pooled analysis of published trials of bupropion SR. In: i8th Annual Meeting of the i Society for Research on Nicotine and Tobacco, Savannah, Georgia (2002).
   Google Scholar
• GONZALES D, POWELL S, BOHM B iet al.: i A pooled analysis confirms smoking abstinence rates with bupropion SR are similar in men and women. In: 4th iEuropean i Conference of the Society for Research on iNicotine and Tobacco, i Santander, Spain (2002).
   Google Scholar
• GONZALES D, BJORNSON W, DURCAN MJ iet al.: i Effects of gender on relapse prevention in smokers treated with bupropion SR. iAm. I Prey Med. i (2002) 22:234–239.
   Google Scholar
• HAYFORD KE, PATTEN CA, RUMMANS TA iet al.: i Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. iBr J. Psychiatry i (1999) 174:173–178.
   Google Scholar
• JOHNSTON JA, FIEDLER-KELLY J, GLOVER ED, SACHS DPL, GRASELATH, DEVEAUGH-GEISS J: Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. iNicotine Tob. Res. i (2001) 3:131–140.
   PubMedGoogle Scholar
• HURT RD, WOLTER TD, RIGOTTI N iet al.: i Bupropion for pharmacologic relapse prevention to smoking. Predictors of outcome. iAddict. Behav. i (2002) 27:493–507.
   Google Scholar
• NIDES M, SACHS D, DURCAN M, JOHNSTON JA: Smoking cessation efficacy and safety of bupropion sustained-release in elderly smokers. In: i5th European Conference of the Socieh, i ifor Research on Nicotine and Tobacco, i Padova, Italy (2003).
   Google Scholar
• CROFT H; HOUSER TL, JAMERSON BD iet al.: i Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. iClin. Ther. i (2002) 24:662–672.
   Google Scholar
• ANDERSON JW, GREENWAY FL, FUJIOKA K iet al.: i Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. iObes. Res. i (2002) 10:633–641.
   Google Scholar
• FERRY LH, JOHNSTON JA: Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience. iInt. Clin. Pract. i (2003) 57:224–230.
   PubMed Web of Science ®Google Scholar
• BOSHIER A, WILTON LV, SHAKIR SAW: Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. iEur. I Clin. Pharmacology i (2003) 59:767-773. Affiliation Serena Tonstad" & J Andrew Johnston2 TAuthor for correspondence
   Google Scholar